IQVIA (IQV)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$203.90-2.08%
Close 2026-07-08 · 1-day change
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IQV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IQV free→IQVIA grows revenue about 7% a year, with $17.25 billion guided for 2026. Profit per share is expected near $12.7 in 2026. The company expands its R&D backlog to $32.7 billion, securing future business. It also increased share buyback authorization to $3.2 billion, showing strong capital return.
Revenue growth is slowing, as shown by the recent guidance cut. Competition from Charles River may hurt market share. Debt issuance raises financial risk. Management is volatile, which may affect execution.
The market prices in about 7% revenue growth and values IQVIA roughly 16% below our fair value of $248. Our fair value is 14% above the Street median. We see room for upside if growth and margins hold, but the recent guidance cut and competition risks temper confidence.
Breaks if: Authorization falls below $3.2 billion
IQVIA's board authorized an additional $2 billion for share repurchases, increasing the total authorization to $3.2 billion.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. Total share repurchase authorization is $3.2 billion. The increase in authorization reflects a strategic capital allocation decision, though actual repurchase activity is not detailed in the current quarter.
“Board authorized the repurchase of an additional $2 billion of IQVIA's common stock, bringing the total remaining authorization to $3.2 billion.”
Breaks if: EPS falls below $12.55 in FY26
Breaks if: R&D backlog falls below $32.4 billion
IQVIA aims to expand its R&D Solutions backlog, which was reported at $32.7 billion.
Stated in 2 of last 2 quarters. R&D Solutions backlog was $32.7 billion in 2025-Q4, up from $32.4 billion in 2025-Q3. The backlog expansion indicates progress in securing future revenue streams, aligning with management's growth focus.
“R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year.”
“R&D Solutions contracted backlog of $32.4 billion, up 4.1% year-over-year.”
Breaks if: revenue falls below $17.15 billion in FY26
IQVIA is reaffirming its full-year 2026 revenue guidance to be between $17,150 million and $17,350 million.
Stated in 2 of last 2 quarters. Revenue was $4,151 million in 2026-Q1. The reaffirmation of the full-year 2026 revenue guidance suggests a consistent focus on growth, with the current quarter's revenue aligning with the guidance trajectory.
“The company is reaffirming its full-year 2026 guidance for revenue to be between $17,150 million and $17,350 million.”
“For the full year of 2026, the company expects revenue to be between $17,150 million to $17,350 million.”